title: A long-term follow-up of zonisamide monotherapy.
abstract: OBJECTIVE
  Several studies have reported the safety and efficacy of zonisamide monotherapy, but studies on its long-term outcomes are limited. This chart review was conducted to evaluate the long-term outcomes of zonisamide monotherapy.
  
  
  METHODS
  The charts were reviewed for 77 patients treated with zonisamide as monotherapy for 6-180 months between May 1985 and December 2003. Outcomes were analyzed by the following subcategories: patients with newly diagnosed epilepsy or with antiepileptic drug-resistant epilepsy, the type of epilepsy, patient age, and treatment period.
  
  
  RESULTS
  Of a total of 77 patients, 49 patients (64%) attained 50% or more reduction of seizure frequency and of those patients 38 (49%) attained 75% or more reduction, with 18 patients (24%) becoming seizure-free from 6 to 180 (median 80.6 +/- 43.6) months of follow-up. Thirty-eight patients (49%) continued zonisamide monotherapy as of December 2003. Proportions of patients having 75% or more reduction in seizure frequency in subcategories were as follows; 56% in patients with newly diagnosed epilepsy and 48% in patients whose treatment was switched to zonisamide monotherapy owing to lack of efficacy of or adverse reaction to previous antiepileptic drugs; 60% in patients with localization-related epilepsies and 38% in patients with generalized epilepsies; and 49% in pediatric patients and 50% in adult patients.
  
  
  CONCLUSIONS
  Long-term zonisamide monotherapy was efficacious in a wide range of patients with epilepsy. Zonisamide did not seem to exhibit a reduction in efficacy during long-term use of up to 180 months.
authors.affiliation: National Epilepsy Center, Shizuoka Medical Institute of Neurological Disorders, Shizuoka, Japan.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Fukushima
authors.forename: Masakazu
authors.initials: M
authors.lastname: Seino
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008499:Medical Records; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D000078305:Zonisamide
chemical_list: D000927:Anticonvulsants; D007555:Isoxazoles; D000078305:Zonisamide